“…A majority of the work has focused on synthesis of new ligand frameworks to chelate copper in a multi-dentate fashion to prevent loss of the Cu 2+ ion under in vivo conditions. Crossbridged TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetracetic acid) derivatives, such as 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A) and 1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexa-aza-bicyclo-[6.6.6]eichosane-1,8-diamine (SarAr), have shown increased copper-complex stability in vivo versus the TETA and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelators (Garrison et al, 2007;Di Bartolo et al, 2001 and. Additionally, derivatives of the triazacyclononane macrocycle have produced improved stability of copper complexes .…”